Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
I would treat this as an urgent patient-safety event and a potential material disclosure issue—not as an earnings-management problem. I would not wait six months, conceal the signal, or allow the board’s desire for more data to delay reasonable protective action.Read the full answer
As CEO, my overriding duty is to balance patient safety, legal/regulatory compliance, fiduciary responsibility, and long-term corporate survival. A 1-in-8,000 risk of liver failure is rare but severe, potentially fatal, and materially unexpected relative to the current label.Read the full answer